Senseonics
IPO
Creators of the first and only Long-term Implantable CGM.
- Headquarters
- Germantown, Maryland
- Employees
- 51–200
- Founded
- 1996
- Business Model
- B2C
- Website
- senseonics.com
About
Senseonics is a publicly traded medical technology company (NYSE: SENS) that develops the Eversense continuous glucose monitoring (CGM) system—the world's first and only long-term implantable CGM for people with diabetes. The Eversense 365 sensor is implanted under the skin and lasts up to 365 days, using fluorescence-based sensing technology paired with a removable smart transmitter and mobile app.